ATE491443T1 - Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen - Google Patents

Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen

Info

Publication number
ATE491443T1
ATE491443T1 AT06290636T AT06290636T ATE491443T1 AT E491443 T1 ATE491443 T1 AT E491443T1 AT 06290636 T AT06290636 T AT 06290636T AT 06290636 T AT06290636 T AT 06290636T AT E491443 T1 ATE491443 T1 AT E491443T1
Authority
AT
Austria
Prior art keywords
agomelatin
medication
treatment
production
bipolar diseases
Prior art date
Application number
AT06290636T
Other languages
English (en)
Inventor
Bodinat Christian De
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE491443(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE491443T1 publication Critical patent/ATE491443T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06290636T 2005-04-20 2006-04-19 Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen ATE491443T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (1)

Publication Number Publication Date
ATE491443T1 true ATE491443T1 (de) 2011-01-15

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06290636T ATE491443T1 (de) 2005-04-20 2006-04-19 Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen

Country Status (41)

Country Link
US (1) US7947743B2 (de)
EP (1) EP1714647B1 (de)
JP (2) JP4580364B2 (de)
KR (2) KR100835451B1 (de)
CN (2) CN1853619B (de)
AP (1) AP2656A (de)
AR (1) AR057277A1 (de)
AT (1) ATE491443T1 (de)
AU (1) AU2006201655B2 (de)
BR (1) BRPI0601285A8 (de)
CA (1) CA2544136C (de)
CR (1) CR9426A (de)
CY (1) CY1111257T1 (de)
DE (1) DE602006018822D1 (de)
DK (1) DK1714647T3 (de)
EA (1) EA013462B1 (de)
ES (1) ES2357901T3 (de)
FR (1) FR2884714B1 (de)
GE (1) GEP20094651B (de)
GT (1) GT200600141A (de)
HR (1) HRP20110083T1 (de)
IL (1) IL186373A (de)
JO (1) JO2666B1 (de)
MA (1) MA28266A1 (de)
ME (1) ME01951B (de)
MY (1) MY143171A (de)
NO (1) NO336010B1 (de)
NZ (1) NZ546630A (de)
PE (1) PE20061337A1 (de)
PL (1) PL1714647T3 (de)
PT (1) PT1714647E (de)
PY (1) PY0610113A (de)
RS (1) RS51659B (de)
SG (1) SG126868A1 (de)
SI (1) SI1714647T1 (de)
TN (1) TNSN07364A1 (de)
TW (2) TW200940049A (de)
UA (1) UA83681C2 (de)
UY (1) UY29470A1 (de)
WO (1) WO2006111653A1 (de)
ZA (1) ZA200603160B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
EP2150525A1 (de) * 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl)-acetamide
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (de) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarker zur Vorhersage der langfristigen Remission bei Depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
PL364640A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität

Also Published As

Publication number Publication date
KR100835451B1 (ko) 2008-06-09
TW200716083A (en) 2007-05-01
CR9426A (es) 2008-02-21
CA2544136A1 (fr) 2006-10-20
IL186373A0 (en) 2008-08-07
RS51659B (sr) 2011-10-31
JP4580364B2 (ja) 2010-11-10
TW200940049A (en) 2009-10-01
AU2006201655B2 (en) 2009-04-23
NO20061705L (no) 2006-10-23
KR20080028389A (ko) 2008-03-31
DE602006018822D1 (de) 2011-01-27
TWI318115B (en) 2009-12-11
KR20060110803A (ko) 2006-10-25
CA2544136C (fr) 2012-02-21
PT1714647E (pt) 2011-01-14
HK1093906A1 (en) 2007-03-16
IL186373A (en) 2012-06-28
FR2884714A1 (fr) 2006-10-27
CN1853619A (zh) 2006-11-01
JP2006316056A (ja) 2006-11-24
HRP20110083T1 (hr) 2011-03-31
US20060240127A1 (en) 2006-10-26
UA83681C2 (uk) 2008-08-11
SG126868A1 (en) 2006-11-29
NO336010B1 (no) 2015-04-20
ME01951B (de) 2011-10-31
JO2666B1 (en) 2012-06-17
AP2656A (en) 2013-05-07
CN102038669A (zh) 2011-05-04
DK1714647T3 (da) 2011-03-07
ES2357901T3 (es) 2011-05-03
UY29470A1 (es) 2006-05-31
EA200600600A1 (ru) 2006-10-27
MA28266A1 (fr) 2006-11-01
ZA200603160B (en) 2007-06-27
GT200600141A (es) 2006-11-22
PE20061337A1 (es) 2007-01-27
JP2010280699A (ja) 2010-12-16
US7947743B2 (en) 2011-05-24
GEP20094651B (en) 2009-03-25
EP1714647A1 (de) 2006-10-25
MY143171A (en) 2011-03-31
NZ546630A (en) 2007-09-28
AR057277A1 (es) 2007-11-28
JP5341037B2 (ja) 2013-11-13
TNSN07364A1 (en) 2008-12-31
EA013462B1 (ru) 2010-04-30
PL1714647T3 (pl) 2011-05-31
SI1714647T1 (sl) 2011-03-31
PY0610113A (es) 2011-01-03
CY1111257T1 (el) 2015-08-05
WO2006111653A1 (fr) 2006-10-26
AU2006201655A1 (en) 2006-11-09
FR2884714B1 (fr) 2011-05-06
BRPI0601285A8 (pt) 2021-03-30
CN1853619B (zh) 2011-02-02
EP1714647B1 (de) 2010-12-15
AP2007004212A0 (en) 2007-10-31
BRPI0601285A (pt) 2006-12-19

Similar Documents

Publication Publication Date Title
ATE512661T1 (de) Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
DE602007008494D1 (de) Verwendung von Agomelatin zur Herstellung von Medikamenten zur Behandlung der generalisierten Angststörung
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
EP2411004A4 (de) Verwendung von andrographolidverbindungen zur behandlung von entzündungen und atemwegserkrankungen
ATE539754T1 (de) Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
ATE501717T1 (de) Einsatz von agomelatin zur herstellung von medikamenten zur behandlung des smith-magenis- syndroms (sms)
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE520393T1 (de) Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen
ATE491443T1 (de) Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen
DE602006005640D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1714647

Country of ref document: EP